Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

DUSA PHARMACEUTICALS INC

Form 4 April 05, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SECURITIES

OMB APPROVAL OMB

3235-0287 Number:

January 31, 2005

0.5

Estimated average

Expires:

burden hours per response...

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

5. Relationship of Reporting Person(s) to

if no longer subject to Section 16. Form 4 or Form 5 obligations

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

may continue. See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person *

COOPER HILL PARTNERS LLC			Symbol DUSA PHARMACEUTICALS INC [DUSA]					Issuer (Check all applicable)			
(Last)	(First)	(Middle)	(Month/	f Earliest Transaction Day/Year)				DirectorX 10% Owner Officer (give title below) Other (specify below)			
767 THIRD AVENUE (Street)			04/03/2006 4. If Amendment, Date Original					6. Individual or Joint/Group Filing(Check			
NEW YOR	Filed(Month/Day/Year)					Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	ty) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any	on Date, if Transactiomr Disposed of (D) Code (Instr. 3, 4 and 5) /Day/Year) (Instr. 8) (A) or)))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Common Stock, par value \$.01 per share	04/03/2006			Code V	Amount 637,008	(D)	Price \$ 7.0005	2,783,400	I	See footnote (1)	
Common Stock, par value \$.01 per share (1)	04/03/2006			J	637,008	A	\$ 7.0005	2,783,400	I	See footnote (1)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5.	6. Date Exerc	cisable and	7. Titl	e and	8. Price of	9. Nu
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orNumber	Expiration D	ate	Amou	nt of	Derivative	Deriv
Security	or Exercise		any	Code	of	(Month/Day/	Year)	Under	lying	Security	Secui
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Derivative	e		Securi	ities	(Instr. 5)	Bene
	Derivative				Securities			(Instr.	3 and 4)		Owne
	Security				Acquired						Follo
	·				(A) or						Repo
					Disposed						Trans
					of (D)						(Instr
					(Instr. 3,						
					4, and 5)						
									Amount		
						Date	Expiration	 .	or		
						Exercisable	Date		Number		
				G 1 1	(A) (B)			of			
				Code V	(A) (D)				Shares		

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

> > X

COOPER HILL PARTNERS LLC 767 THIRD AVENUE

NEW YORK, NY 10017

Signatures

/s/ Peter Freer 04/05/2006 **Signature of Date Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This filing reflects a transfer between and among the reporting persons and does not reflect a change in the overall beneficial ownership **(1)** of the reporting persons as previously filed.

Remarks:

CLSP, L.P. ("CLSP"), CLSP II, L.P. ("CLSP II"), CLSP/SBS I, L.P. ("CLSP/SBS I"), and CLSP/SBS II, L.P. ("CLSP/SBS II") each private investment partnerships, the sole general partner of which is Cooper Hill Partners, LLC. As the sole general partner of CLSP, CLSP II, CLSP/SBS I, and CLSP/SBS II, Cooper Hill Partners, LLC has the power to vote and dispose of the Securities owned by each of CLSP, CLSP II, CLSP/SBS I, and CLSP/SBS II and, accordingly, may be deemed the "beneficia owner" of such Securities. The managing member of Cooper Hill Partners, LLC is Casdin Capital, LLC. Purusant to an

Reporting Owners 2

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 4

investment advisory contract, Cooper Hill Partners, L.P. currently has the power to vote and dispose of the Securities held for the account of CLSP Overseas, Ltd. and, accordingly, may be deemed the "beneficial owner" of such Securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.